Yixintang Pharmaceutical (SZ:002727)2024-07-09 10:29Financial Projections - The estimated net profit for the first half of 2024 is projected to be between 26,218.20 million CNY and 33,995.18 million CNY, representing a decline of 48.04% to 32.63% compared to the same period last year[5]. - The net profit after deducting non-recurring gains and losses is expected to be between 27,774.96 million CNY and 35,551.95 million CNY, down by 45% to 29.6% year-over-year[5]. - Basic earnings per share are projected to be between 0.4399 CNY and 0.5704 CNY, compared to 0.8489 CNY in the same period last year[5]. Operational Challenges - The decline in net profit is attributed to increased operating costs from the opening of new stores and intensified competition, leading to a decrease in same-store sales[6]. Reporting and Compliance - The financial data presented is preliminary and will be detailed in the company's 2024 semi-annual report[9]. - The company is currently undergoing self-inspection and reporting related to a meeting with the National Medical Insurance Bureau, with no final conclusions yet[10].